Biosimilar Market Analysis 2022, Size, Share, Industry Trends Forecast by 2028

The "Biosimilar Market" was valued at US$ 18,435.89 million in 2021 and is expected to reach US$ 136,069.53 million by 2028; it is estimated to record a CAGR of 34.8% from 2022 to 2028.

The biosimilars market growth is attributed to the increasing prevalence of chronic diseases, the cost-effectiveness of biosimilar drugs, and the increase in approvals of biosimilars. However, high-cost involvement and complexities in biosimilar product manufacturing restrain the biosimilars market growth.

The Food and Drug Administration (FDA) approves biosimilar products and provides the scientific and regulatory advice needed to bring safe and effective biosimilars to market. The approval of biosimilar products can improve patient care by increasing the number of medication options at potentially lower costs.

Get a Sample PDF of report at: https://www.premiummarketinsights.com/sample/TIP00000686?utm_source=OpenPr&utm_medium=10640

The List of Companies -
1. Biocon Ltd
2. Sanofi-Aventis
3. Celltrion Inc.
4. Amgen Inc.
5. Pfizer Inc.
6. Samsung Bioepis
7. Sanofi SA
8. Coherus BioSciences Inc
9. Dr. Reddy's Laboratories Ltd
10. Eli Lilly and Co
11. Sandoz AG
12. Teva Pharmaceutical Industries Ltd.

Disease Indication-Based Insights
Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2021. The market for the autoimmune diseases segment is likely to grow at the highest rate during the forecast period.

Drug Class-Based Insights
The biosimilars market, based on drug class, is segmented into Granulocyte Colony-stimulating Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-stimulating Stimulating Agents, and Others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2021 and is expected to register the highest CAGR of 35.8% during the forecast period.

Route of Administration -Based Insights
Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2021 and is expected to register the highest CAGR of 36.0% during the forecast period.

End User-Based Insights
The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2021, whereas the homecare segment is expected to register the highest CAGR of 36.6% during the forecast period.

Get Full Report: https://www.premiummarketinsights.com/reports-tip/biosimilars-market

By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.

Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.

There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.

The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:

In January 2022, Samsung Biologics and Biogen entered a joint venture, forming Samsung Bioepis. Samsung Bioepis launched biosimilars of etanercept, adalimumab, infliximab, and trastuzumab in Europe, with others in the pipeline. It has also entered into many commercialization partnerships.

In March 2021, The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP), in collaboration with Pfizer Inc. to launch ten projects, announced that it had received funding to support innovative approaches to enhance the processes related to appropriate biosimilar adoption in oncology.

In September 2019, Henlius announced a strategic collaboration with Ascentage Pharma to conduct clinical trials of the combination therapy between Rituximab Injection, the first launched product by Henlius, and APG-2575, a novel and orally administered Bcl-2 selective inhibitor developed by Ascentage Pharma, for the treatment of chronic lymphocytic leukemia (CLL) in China.

In June 2019, STADA and Xbrane Biopharma expanded their biosimilar collaboration to evaluate potential collaboration on additional products. The two companies stated that they will focus on biosimilars of originator products that will face patent expiry from 2025 to 2030.
Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.

Buy a copy of this research report at @: https://www.premiummarketinsights.com/buy/TIP00000686?utm_source=OpenPr&utm_medium=10640

Other Reports:
Activated Carbon Market Insights, Global Trend And Revenue Growth Forecast Till 2028 https://www.marketwatch.com/press-release/activated-carbon-market-insights-global-trend-and-revenue-growth-forecast-till-2028-2023-06-02?mod=search_headline

Bathroom Vanities Market- Overview, Opportunities And Challenges Forecast To 2028 https://www.marketwatch.com/press-release/bathroom-vanities-market--overview-opportunities-and-challenges-forecast-to-2028-2023-06-02?mod=search_headline

Botulinum Toxin Market Demand, Size, Share, Industry Trend, Top Key Players Forecast 2028 https://www.marketwatch.com/press-release/botulinum-toxin-market-demand-size-share-industry-trend-top-key-players-forecast-2028-2023-06-02?mod=search_headline

Dried Honey Market- Global Industry Size, Outlook, Share, Demand, Manufacturers and 2028 Forecast https://www.marketwatch.com/press-release/dried-honey-market--global-industry-size-outlook-share-demand-manufacturers-and-2028-forecast-2023-06-02?mod=search_headline

Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email: sales@premiummarketinsights.com

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

This release was published on openPR.